Lexicon Pharma (LXRX) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.27 --0%
EPS Growth %: -600.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: -600.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $376 million versus the consensus estimate of $360 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy rejects short-seller report on finances and supply chain
- Simply Good Foods posts Q3 loss, cuts fiscal 2026 outlook
- Baird Starts Cohu (COHU) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
